Fresenius Medical Care AG & Co. FMS reported third-quarter 2025 adjusted earnings per share (EPS) of 64 cents, which surpassed the Zacks Consensus Estimate by 8.47%. The bottom line improved 35.8% ...
Zacks Investment Research on MSN
Reasons to hold Fresenius Medical stock in your portfolio for now
Fresenius Medical Care AG & Co. FMS is well-positioned for growth, backed by strategic acquisitions and partnerships, as well ...
Fresenius Medical Care ( ($FMS) ) has provided an announcement. Fresenius Medical Care announced the appointment of Charles Hugh-Jones as the new ...
Fresenius Medical Care (FMS) is rated a 'Buy,' citing strong fundamentals. FMS demonstrates robust revenue growth, margin expansion, and dividend safety, with a new HVHDF product rollout expected to ...
CVS Health CVS and Fresenius Medical Care AG & Co. FMS are two major players in the healthcare services sector, but with distinct areas of focus. CVS Health is a leading health solutions company ...
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback